Navigation Links
Poniard Announces Positive Efficacy and Safety Data From Phase 1 Trial of Picoplatin in Multiple Tumor Types Including Ovarian Cancer
Date:6/1/2008

- Poster Presented at ASCO Annual Meeting -

SOUTH SAN FRANCISCO, Calif. and CHICAGO, June 1 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced safety and efficacy results from a previously unpublished Phase 1 clinical trial of picoplatin and liposomal doxorubicin in patients with advanced solid tumors, including ovarian cancer. Results demonstrated signals of clinical activity and acceptable toxicity with this combination.

Picoplatin, the Company's lead product candidate, is a new generation platinum chemotherapy agent with the potential to address multiple indications, combinations and formulations. Doxorubicin, the active pharmaceutical ingredient of liposomal doxorubicin, is used in the treatment of a wide range of tumor types (e.g., breast, ovarian, lung, gastric, liver, bladder, thyroid, lymphomas and leukemias). Liposomal doxorubicin is approved for the treatment of patients with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy. The standard of care for non-platinum-based chemotherapy in relapsed ovarian cancer is liposomal doxorubicin.

"The phase 1 trial in advanced solid tumors showed that both agents could be combined with an acceptable toxicity profile," said Don S. Dizon, M.D., assistant professor of obstetrics-gynecology and medicine at the Warren Alpert Medical School of Brown University. "In addition, the response rates observed with picoplatin with this new combination, particularly in those women with ovarian cancer, are promising and warrant further study. Advanced ovarian cancer is among the deadliest cancers, and patients who have failed initial therapy typically
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer
2. Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer
3. Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting
4. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
5. Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer
6. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
7. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
8. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
10. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
11. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... PHILADELPHIA , April 24, 2015  Lannett Company, ... has amended and increased its five-year revolving credit facility ... includes an accordion feature that will allow the company ... an additional $30.0 million, subject to securing additional commitments ... date of the credit facility remains December 18, 2018. ...
(Date:4/24/2015)... Mass. , April 24, 2015  Blueprint ... BLU-554, a selective and potent inhibitor of fibroblast ... activity in models of hepatocellular carcinoma (HCC) that ... therapeutic candidate, BLU-554 induced complete tumor regression in ... an FGFR4-activating ligand at the highest dose levels. ...
(Date:4/23/2015)... , April 23, 2015 Once again, ... strengthening our commitment to patient safety. BeaconMedaes, ... fight against infectious disease. The next generation ... Medical gas sensors are now mounted in the assembly, ... need to open ceiling tiles potentially releasing dust spores ...
Breaking Medicine Technology:Lannett Expands Revolving Credit Facility To $120 Million 2Blueprint Medicines Presents New Preclinical Data Demonstrating Its Drug Candidate BLU-554 Induces Significant Tumor Regression in Models of Hepatocellular Carcinoma 2Blueprint Medicines Presents New Preclinical Data Demonstrating Its Drug Candidate BLU-554 Induces Significant Tumor Regression in Models of Hepatocellular Carcinoma 3BeaconMedaes launches new Zone Valve Box Assembly 2
... REDWOOD CITY, Calif., Aug. 17 Cardica, Inc. (Nasdaq: ... Intuitive Surgical, Inc. have entered into a license agreement ... intellectual property, which relates to tissue cutting, stapling and ... to the license agreement, Cardica and Intuitive may also ...
... (Nasdaq: BMRN ) announced today that it ... company developing enzyme replacement therapies (ERT) for the treatment ... ZC-701, a novel fusion of insulin-like growth factor 2 ... Under the terms of the agreement, BioMarin ...
Cached Medicine Technology:Cardica and Intuitive Surgical Enter Into License Agreement 2Cardica and Intuitive Surgical Enter Into License Agreement 3BioMarin Acquires ZyStor Therapeutics, Inc. 2BioMarin Acquires ZyStor Therapeutics, Inc. 3BioMarin Acquires ZyStor Therapeutics, Inc. 4BioMarin Acquires ZyStor Therapeutics, Inc. 5
(Date:4/25/2015)... Sports controversies continue to revolve around issues of ... the case with the Miami Dolphins and Richie Incognito, or off ... Ray Rice domestic abuse case. In a recent episode of ... the implications of locker room culture on teams. He examines what ... should do to improve the locker room as a work place. ...
(Date:4/24/2015)... Illinois (PRWEB) April 24, 2015 Multi ... includes septic tank pumping ( http://www.zeitersseptics.com/multi-customer-discount.html ) of 1000-1500 ... to start the program. This does not include any ... applicable. Save $25-$65 per person. If someone is part ... or two tanks totaling approximately 2500 gallons or more, ...
(Date:4/24/2015)... York, New York (PRWEB) April 24, 2015 ... continue to move forward in the federal multidistrict ... South Carolina. According to court documents, the parties ... Report on April 16th detailing, among other things, ... report notes that counsel for both plaintiffs and ...
(Date:4/24/2015)... Carinsurancequotesinfo.com has released a new blog ... to qualify for auto insurance as a ... auto insurance online, without having to follow a special ... parents can reduce their auto insurance expenses. The tips ... explained. , Clients can now visit an insurance ...
(Date:4/24/2015)... Joseph, Missouri (PRWEB) April 24, 2015 ... for veterinarians , UGA is now proud to be ... the care of 16,000 animals a year. This partnership ... care for their animals. , After providing an ... Missouri Veterinary Medical Teaching Hospital (VMTH) wanted to increase ...
Breaking Medicine News(10 mins):Health News:David Steele Discusses Locker Room Culture on SCI TV 2Health News:David Steele Discusses Locker Room Culture on SCI TV 3Health News:Zeiter's Septics Inc. Offers Multi Customer Septic Tank Cleaning Program in Cook, Putnam & Will Counties in May 2015 2Health News:Zeiter's Septics Inc. Offers Multi Customer Septic Tank Cleaning Program in Cook, Putnam & Will Counties in May 2015 3Health News:Federal Lipitor Lawsuits Progress, as New Status Report Details Preparation for Upcoming Bellwether Trials 2Health News:Federal Lipitor Lawsuits Progress, as New Status Report Details Preparation for Upcoming Bellwether Trials 3Health News:Auto Insurance Discounts for Single Parents - How to Qualify for Low Rates 2Health News:University of Missouri Veterinary Medical Teaching Hospital Teams with UGA 2
... ORLANDO, Fla., Aug. 19 Valensa International ... dramatically increased the stability and shelf-life of the powerful, ... 7-year shelf-life study of its Zanthin(R) natural astaxanthin that ... Haematococcus pluvialis, bolstered by Valensa,s proprietary O2B(R) Peroxidation Blocker ...
... , , WASHINGTON, Aug. 19 ... August 2009: , , The "Bulletin," which is ... ), brings you the latest issues and news affecting people with ... , click on "Online mailing list archives," select "NCD-NEWS-L," click on ...
... , ... software-based 3D scanner includes 3D scan data processing capabilities and supports scanning in 360°. ... Vancouver, BC (PRWEB) August 19, ... of FlexScan3D 2.5 , the latest version of its 3D scanning software. New ...
... ... stepper motors presented by NMB. These popular sizes are ideal for medical and industrial applications. ... Chatsworth, CA (PRWEB) August 19, 2009 ... of standard hybrid stepper motors. , , , , ,The standard hybrid line includes the ...
... , COLUMBIA, S.C., Aug. 19 ... technology and knowledge discovery software, announced today that their life science research ... the 200,000 registered user mark . , , (Logo: ... in less than 18 months is very positive and we expect that ...
... , PACE(R) Programs Open Doors to Highlight ... WASHINGTON, Aug. 19 In celebration of National Senior Citizens Day, ... many of the individual Programs of All-inclusive Care for the Elderly ... through health fairs and open houses. Designed to serve individuals ...
Cached Medicine News:Health News:Astaxanthin Stability Breakthrough Achieved by Valensa 2Health News:Astaxanthin Stability Breakthrough Achieved by Valensa 3Health News:National Council on Disability Monthly Bulletin for August 2009 2Health News:National Council on Disability Monthly Bulletin for August 2009 3Health News:National Council on Disability Monthly Bulletin for August 2009 4Health News:National Council on Disability Monthly Bulletin for August 2009 5Health News:National Council on Disability Monthly Bulletin for August 2009 6Health News:National Council on Disability Monthly Bulletin for August 2009 7Health News:3D3 Solutions Unveils FlexScan3D Version 2.5 3D Scanner; New Features Speed Up the 3D Scanning Process 2Health News:NMB's New Series of Standard Hybrid Stepper Motors Now Available 2Health News:Collexis BiomedExperts.com Achieves 200,000 Registered Users 2Health News:Collexis BiomedExperts.com Achieves 200,000 Registered Users 3Health News:National Senior Citizens Day Celebrated August 21 Amid Health Care Reform Debate 2Health News:National Senior Citizens Day Celebrated August 21 Amid Health Care Reform Debate 3
... Insulin-like growth factor I (IGF-I or somatomedin C) ... the liver. It acts as a potent mitogen ... to specific cell-surface receptors. In the circulation, IGF-I ... to regulate the actions of IGF-I by modulating ...
... a potent naturally occurring androgen produced ... cholestenone 5a-reductase [1]. The concentrations ... peripheral tissues, including genital skin and ... in apparent association with the nuclear ...
The Bard Ellik Bladder Evacuator is designed for ease of maneuverability during the removal of tissue sections during transurethral prostatectomy, TURPs, bladder biopsy, etc....
... The BT table comes in two ... movements, and the BT5, which offers five. ... the tables adjust to suit your needs. ... and hand controls, side rails, ankle/foot supports, ...
Medicine Products: